All In MedTech

Device Trial Radar · NCT03762200

SURGICEL® Powder in Controlling Mild or Moderate Parenchymal or Soft Tissue Intraoperative Bleeding in Adult Subjects

A Prospective, Clinical Study Evaluating the Safety and Haemostatic Effectiveness of SURGICEL® Powder, in Mild or Moderate Parenchymal or Soft Tissue Bleeding During General, Gynaecological, Urological, and Cardiothoracic Surgery

Last checked: Nov 20, 2026Latest source record: Jul 26, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

103

Actual

Start

Nov 26, 2018

Primary completion

Dec 2, 2019

Study completion Jun 3, 2020

Sponsor

Lead sponsor
Ethicon, Inc.Public (JNJ)
Sponsor type
Industry
First posted
Dec 3, 2018

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, single arm, multicentre, multispecialty, post market, clinical study evaluating SURGICEL Powder as an adjunct to achieve haemostasis (control bleeding) when conventional methods of control are impractical or ineffective during surgery (open, laparoscopic or thoracoscopic) in adult subjects (18 years or older). After application of SURGICEL Powder, the Target Bleeding Site (TBS) will be assessed for haemostasis (no detectable bleeding) at 3, 5, and 10 minutes from application and prior to initiation of closure. All enrolled subjects will be followed post-operatively through discharge and again at 30 days and 6 months post-surgery via phone call or office visit.

Conditions

  • Hemorrhage

Interventions

  • SURGICEL PowderDevice

    SURGICEL Powder is a topical absorbable hemostatic treatment made of oxidized regenerated cellulose (ORC) - plant material

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Haemostatic Success at 5 MinutesTime frame: From application of SURGICEL Powder to 5 minutes after application

Locations

8 sites in 2 countries. Site status is shown where the registry gives one.

  • Ziekenhuis Oost Limburg

    Genk, Belgium

  • Universitair Ziekenhuis Gent

    Ghent, Belgium

  • Cambridge University Hospitals NHS Trust (Addenbrooke's Hospital)

    Cambridge, United Kingdom

5 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.